Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial.
Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial.
复制标题
DOI：
10.18632/oncotarget.21291
复制
发表时间：
2017-11-07
期刊：
影响因子：
--
通讯作者：
Laurent-Puig P
中科院分区：
文献类型：
--
作者：
Pugh S;Thiébaut R;Bridgewater J;Grisoni ML;Moutasim K;Rousseau F;Thomas GJ;Griffiths G;Liebaert F;Primrose J;Laurent-Puig P
miR-31- 3 p高表达与接受抗EGFR治疗的KRAS野生型（WT）晚期结直肠癌患者的不良结局相关。本研究评估了新EPOC研究中入组的可手术结直肠肝转移（LM）患者的miR-31- 3 p表达。在来自149名KRAS WT患者的原发性肿瘤（PT）中测量miR-31- 3 p表达，所述患者包括71名接受单独化疗（CT）和78名接受化疗加西妥昔单抗（CTX）的患者。基于miR-31- 3 p表达水平将每个治疗组分成三分位数。还在94名具有肿瘤组织的患者的LM中测量了miR-31- 3 p表达。CTX组中miR-31- 3 p表达中等或高水平的合并人群的中位无进展生存期短于CT组（26.7个月vs 12.3个月，HR=2.28 95%CI 1.27; 4.09 p=0.006）。低miR-31- 3 p表达者的结局相似，与治疗无关（HR=1.06 95%CI 0.43; 2.61 p=0.9）。在CT组中，配对PT和LM样本之间的MiR-31- 3 p表达相关，但在CTX组中不相关。在新EPOC研究中，miR-31- 3 p表达低的患者不会因添加西妥昔单抗而受到损害。这支持miR-31- 3 p作为KRAS WT晚期结直肠癌中抗EGFR治疗的有前景的预测生物标志物。
High miR-31-3p expression is associated with inferior outcomes in KRAS wild-type (WT) advanced colorectal cancer patients treated with anti-EGFR therapy. This study evaluated miR-31-3p expression in patients with operable colorectal liver metastases (LM) enrolled in the New EPOC study. MiR-31-3p expression was measured in primary tumors (PT) from 149 KRAS WT patients including 71 receiving chemotherapy alone (CT) and 78 receiving chemotherapy plus cetuximab (CTX). Each treatment arm was split into tertiles based on miR-31-3p expression levels. MiR-31-3p expression was also measured in LM from 94 patients with tumor tissue available. The median progression-free survival for the combined populations with mid or high miR-31-3p expression was shorter in the CTX versus the CT arm (26.7 months versus 12.3 months, HR=2.28 95%CI 1.27; 4.09 p=0.006). Low miR-31-3p expressers had similar outcomes irrespective of treatment (HR=1.06 95%CI 0.43; 2.61 p=0.9). MiR-31-3p expression was correlated between paired PT and LM samples in the CT group but not in the CTX group. Patients with low miR-31-3p expression in the New EPOC study were not harmed by the addition of cetuximab. This supports miR-31-3p as a promising predictive biomarker for anti-EGFR therapy in KRAS WT advanced colorectal cancer.
登录
查看更多内容
影响因子：
3.8
作者：
Schee K;Boye K;Abrahamsen TW;Fodstad Ø;Flatmark K
通讯作者：
Flatmark K
影响因子：
--
作者：
Mlcochova J;Faltejskova-Vychytilova P;Ferracin M;Zagatti B;Radova L;Svoboda M;Nemecek R;John S;Kiss I;Vyzula R;Negrini M;Slaby O
通讯作者：
Slaby O
影响因子：
1.9
作者：
Mosakhani, Neda;Lahti, Leo;Sarhadi, Virinder Kaur
通讯作者：
Sarhadi, Virinder Kaur
影响因子：
11.2
作者：
Liu, Chung-Ji;Tsai, Meng-Miao;Chang, Kuo-Wei
通讯作者：
Chang, Kuo-Wei
影响因子：
51.1
作者：
Primrose, John;Falk, Stephen;Bridgewater, John
通讯作者：
Bridgewater, John